Last updated: 23 days ago
AstraZeneca's Gefurulimab Trial Report: Promising Results for gMG Treatment
This SEC Form 6-K reveals AstraZeneca's Phase III results for Gefurulimab in treating gMG, highlighting significant improvements in daily living activities and a solid safety profile.